The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

mCRC Updates: FOLFOXIRI+Bev for Unresectable Disease, CEND-1+Neoadjuvant FOLFIRINOX, CRS-HIPEC for Colorectal Peritoneal Carcinomatosis, Oligometastatic Disease

30 views
May 17, 2021
0 Comments
Login to view comments. Click here to Login
2021 KUMC Virtual Multidisciplinary Oncology Review